Relying on Renagel

In the second of a two-part series focused on Genzyme's European operations, In Vivo Europe Rx looks at how Genzyme is addressing the challenges facing Renagel's uptake in Europe-cost-conscious reimbursement authorities, cheaper competitors and conservative physicians-in order to secure its most important mid-term growth source.

Genzyme Corp. 's flagship product, Gaucher's disease treatment imiglucerase (Cerezyme) is the group's largest, and the one around which the US biotech's now-extensive European operations were built. Yet Cerezyme, whose $570 million (€584 million) sales last year accounted for more than half of group worldwide revenues, in May last year lost the orphan drug designation which had thus far held off competition, allowing the company to penetrate more than half the estimated market, according to some analysts. And while the nearest-term threat to Cerezyme, Oxford GlycoSciences PLC 's orally available miglustat (Zavesca) was rejected by the FDA in June, Europe's Committee for Proprietary Medicinal Products has taken a more favorable view, recommending approval a month later for the drug (See "Actelion: Pharmacovigilant," this issue Also see "Actelion: Pharmacovigilant" - In Vivo, 1 September, 2002.). Given the competition, and the fact that the worldwide population of Gaucher's patients is just a few thousand, Cerezyme's growth potential remains limited.

Instead, more than half of the company's growth through 2005 will come, according to SG Cowen, from sevelamer (Renagel), a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.